E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Gastroesophageal Reflux Disease (GERD) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the PK profile of single and repeated doses of rabeprazole sodium in subjects 12 to 16 years of age with a diagnosis of, or symptoms of, GERD. |
|
E.2.2 | Secondary objectives of the trial |
To collect information on the safety of single and repeated doses of rabeprazole sodium. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females age 12 to 16 years, with a clinical diagnosis of, or symptoms of, GERD.
2. Subjects had to be able and willing to take the required number of test drug tablets.
3. The ability of the child to swallow an intact tablet had to be confirmed by the site at screening by history taking.
4. Minimum weight of 30 kg.
5. Willingness of the subject and ability to give assent to participate.
6. The subject's parent or guardian provided written informed consent.
7. Post-pubertal females were required to abstain from sexual relations during the course of the study. |
|
E.4 | Principal exclusion criteria |
1. Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric or cardiovascular system abnormalities, unless the Sponsor and Investigator agreed that the nature and severity of any abnormality was unlikely to interfere with the conduct of the study, the interpretation of study results, or the health of the subject during the study.
2. Females who were pregnant, lactating or had a positive urine beta-human chorionic gonadotropin (hCG) laboratory result.
3. Subjects who were unwilling or unable to refrain from smoking or drinking alcohol starting from 48 hours prior to screening and dosing, through the end of the study, and/or a positive urine drug screen.
4. Subjects who were unwilling or unable to abide by the requirements of the study or who violated the prohibitions and restrictions of the study defined in the Study Protocol.
5. Any condition, which in the opinion of the Investigator or Sponsor, would make the subject unsuitable for the study.
6. Participation in another investigational drug study within 30 days prior to drug administration.
7. A subject history of drug allergies or sensitivity to proton pump inhibitors or to their inactive ingredients.
8. A subject history of clinically significant bacterial or viral infection within one month of screening.
9. Subject history of definitive acid-lowering surgery or previous esophageal or gastric surgery, with the exception of a simple closure of a perforated ulcer.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean peak plasma concentration (Cmax)
Mean time to peak concentration (tmax)
Mean elimination half-life (t1/2) during the apparent terminal disposition phase
Mean area under the plasma concentration-time curve from time zero to time (AUC0-t)
Mean area under the plasma concentration-time curve from time 0 to infinity (AUC0- ∞)
Accumulation factor (Rac)
Average plasma concentration at steady state (Cav ss)
Apparent clearance (CL/F)
Apparent volume of distribution (Vz/F)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1 (predose, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, and 12 hours post-dose) , Days 2 (pre-dose and 24 hour post-dose), Days 3, 4 (pre-dose), and Day 5 or 7 (predose, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, and 12 hours post-dose) |
|
E.5.2 | Secondary end point(s) |
Number of participants with treatment emergent adverse events (TEAEs) and Serious adverse events (SAEs) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
For each participant, from the date of signing of informed consent up to approximately 8 days |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Single and Multiple Dose Pharmacokinetics and Safety Study in 12 to 16 year old subjects |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Administration of the 10 mg dose will be completed before administration of the 20 mg dose |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Different dosages of Rabeprazole sodium (10 mg and 20 mg doses) are being studied |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 9 |